Literature DB >> 22000706

Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients.

Jounhong Ryan Cho1, Dae Lim Koo, Eun Yeon Joo, So Mi Yoon, Eunji Ju, James Lee, Dae Young Kim, Seung Bong Hong.   

Abstract

OBJECTIVE: To investigate the cognitive effect of levetiracetam (LEV) monotherapy with quantitative electroencephalogram (EEG) analysis and neuropsychological (NP) tests.
METHODS: Twenty-two drug-naïve epilepsy patients were enrolled. EEG recordings were performed before and after LEV therapy. Relative power of discrete frequency bands was computed, as well as alpha peak frequency (APF) at occipital electrodes. Eighteen patients performed a battery of NP tests twice across LEV treatment.
RESULTS: LEV therapy decreased the power of delta (1-3 Hz, p<0.01) and theta (3-7 Hz, p<0.05) bands and increased that of alpha-2 (10-13 Hz, p<0.05) and beta-2 (19-24 Hz, p<0.05) bands. Region-specific spectral change was observed: delta power change was significant in fronto-polar region, theta in anterior region, alpha-2 in broad region, and beta-2 in left fronto-central region. APF change was not significant. Improvement in diverse NP tests requiring attention, working memory, language and executive function was observed. Change in theta, alpha-2, and beta-2 power was correlated with improvement in several NP tests.
CONCLUSIONS: Our data suggest LEV is associated with acceleration of background EEG frequencies and improved cognitive function. Change in frequency band power could predict improvement in several cognitive domains across LEV therapy. SIGNIFICANCE: Combined study of quantitative EEG analysis and NP tests can be useful in identifying cognitive effect of antiepileptic drugs.
Copyright © 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000706     DOI: 10.1016/j.clinph.2011.09.012

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  17 in total

1.  The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study.

Authors:  A Zarabla; S Ungania; A Cacciatore; A Maialetti; G Petreri; A Mengarelli; A Spadea; F Marchesi; D Renzi; Svitlana Gumenyuk; L Strigari; Marta Maschio
Journal:  Funct Neurol       Date:  2017 Oct/Dec

2.  Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes.

Authors:  Qirui Zhang; Fang Yang; Zheng Hu; Zhiqiang Zhang; Qiang Xu; Mantini Dante; Han Wu; Zhipeng Li; Qian Li; Kai Li; Guangming Lu
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

3.  QPEEG analysis of the effects of sodium valproate on adult Chinese patients with generalized tonic-clonic seizures.

Authors:  Jiamei Guo; Dan Wang; Min Ren; Bo Xiong; Zengyou Li; Xuefeng Wang; Kebin Zeng
Journal:  Metab Brain Dis       Date:  2014-05-10       Impact factor: 3.584

4.  Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia.

Authors:  Marta Maschio; Francesco Marchesi; Sabrina Dispenza; Loredana Dinapoli; Francesca Sperati; Gianluca Petreri; Svitlana Gumenyuk; Maria Laura Dessanti; Alessia Zarabla; Tonino Cantelmi; Andrea Mengarelli
Journal:  Cogn Neurodyn       Date:  2016-01-13       Impact factor: 5.082

5.  Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.

Authors:  Clifford M Knapp; Domenic A Ciraulo; Ofra Sarid-Segal; Mark A Richardson; Eric Devine; Chris C Streeter; Marlene Oscar-Berman; Caitlin Surprise; Laurie Colaneri; Meghan Putnam; Megan Waters; Courtney Richambault
Journal:  J Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.153

Review 6.  Post-traumatic epilepsy: current and emerging treatment options.

Authors:  Jerzy P Szaflarski; Yara Nazzal; Laura E Dreer
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-11       Impact factor: 2.570

7.  Changes in background electroencephalography and regional cerebral glucose metabolism in focal epilepsy patients after 1-month administration of levetiracetam.

Authors:  Seong Hoon Kim; Sung-Chul Lim; Woojun Kim; Oh-Hun Kwon; Chan Mi Kim; Jong-Min Lee; Young-Min Shon
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-27       Impact factor: 2.570

8.  Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder.

Authors:  Minjian Wang; Li Jiang; Xiaoju Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-31       Impact factor: 2.570

9.  The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach.

Authors:  Julio Cesar Magalhães; Mariana Gongora; Renan Vicente; Juliana Bittencourt; Guaraci Tanaka; Bruna Velasques; Silmar Teixeira; Gledys Morato; Luis F Basile; Oscar Arias-Carrión; Fernando A M S Pompeu; Mauricio Cagy; Pedro Ribeiro
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

10.  Effect of oxcarbazepine on background EEG activity and cognition in epilepsy.

Authors:  Sung Min Kim; Jin-Young Song; Chany Lee; Hyang Woon Lee; Ji Young Kim; Seung Bong Hong; Ki-Young Jung
Journal:  J Epilepsy Res       Date:  2013-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.